Why did MOLN.SW stock fall pre-market today?

MOLN.SW stock fell **11.14%** pre-market largely on higher volume, sector weakness and lack of fresh clinical news. Traders pointed to profit-taking after recent gains and uncertainty ahead of the next earnings update on 03 Jun 2026.

What is Meyka AI's forecast for MOLN.SW stock?

Meyka AI's forecast model projects a one‑year price of **CHF2.35**, a monthly **CHF2.97** and a quarterly **CHF2.64**. The one‑year projection implies roughly **-29.89%** from the current **CHF3.35**. Forecasts are model outputs, not guarantees.

Is MOLN.SW stock a buy based on fundamentals?

Fundamentally, MOLN.SW shows strong cash per share (**CHF2.79**) but negative EPS (**-1.62**) and negative operating cash flow. Meyka AI assigns a **B** grade and suggests **HOLD**, reflecting mixed growth and balance‑sheet signals.

Which price levels should traders watch for MOLN.SW stock?

Key short‑term levels: support near **CHF3.35** and resistance near **CHF3.80**. Watch the 50‑day average **CHF3.51** and the 200‑day average **CHF3.17** for trend context and volume spikes for validation of moves.

CH Stocks

MOLN.SW down 11.14% pre-market Mar 2026: Molecular Partners CHF3.35 (SIX): view

ByHuzaifa Zahoor March 16, 2026

MOLN.SW stock fell 11.14% pre-market to CHF3.35 on 16 Mar 2026 on the SIX exchange after a sharp intraday gap lower and heavy trade (volume 50,587.00). The move leaves the biotech name well off its year high of CHF4.14 and above the year low of CHF2.70. Investors are reacting to mixed pipeline signals and a cautious market tone in Swiss healthcare. We outline the drivers, valuation, technicals and a model forecast to frame what the drop means for holders and traders.